China Securities News (Yan Ximeng, Reporter Song Weiping) — Recently, two key members of Takeda Pharmaceutical Company Limited’s Global Management Committee—Ramona Sequeira, President of Takeda’s Global Biopharmaceuticals and International Markets Business Group, and Gabriele Ricci, Takeda’s Global Chief Digital Technology Officer—made their first visit to China after assuming their roles. At a recent media meeting, executives from Takeda Pharmaceutical expressed that China is one of the most important strategic markets for Takeda globally. As the "Broaden and Deepen China" strategy continues to be implemented, China will become Takeda's second-largest market worldwide. Takeda Pharmaceutical will continue to increase its investment in the Chinese market, accelerate the introduction of innovative achievements in core business areas, strengthen innovative collaborations with local Chinese partners, jointly enhance patients' quality of life and well-being, and promote high-quality development in innovative biomedicine and digital healthcare industries.
It is reported that during the visit of senior executives from Takeda Pharmaceutical’s Global Management Committee to China, Takeda Pharmaceutical announced two significant collaborations. The first is an exclusive commercial collaboration in the field of Hemophilia B between Takeda China and Belief BioMed Group. This marks another major collaboration between Takeda and innovative Chinese pharmaceutical enterprises, demonstrating Takeda's commitment and confidence in further investing in the Chinese market through concrete actions. The second collaboration involves Takeda China signing a Memorandum of Understanding with the Fudan University Institute of Intelligent Medicine to jointly establish the Takeda Digital Intelligence Innovation Research Institute. Both parties will leverage their respective strengths to promote early-stage fundamental research, synergistically empower the entire chain of resources encompassing government, industry, academia, research, medical, and capital, drive transformation in the digital healthcare sector, and deliver original and groundbreaking digital healthcare solutions for patients in China and around the world.
Relying on Takeda China's profound accumulation in key therapeutic areas and future product pipelines, the Takeda Digital Intelligence Innovation Research Institute will closely collaborate with the Fudan University Intelligent Medicine Research Institute. Both parties will work together to carry out innovative research topics and conceptual models covering screening, diagnosis, and companion treatment. Based on an evidence-based ecosystem, they will accelerate the commercialization of breakthrough results and explore innovative business models.
The 6th China International Import Expo (CIIE) is approaching as scheduled. As a participant, witness, and beneficiary of the CIIE, Takeda will accelerate the introduction of cutting-edge innovative achievements to benefit a broader range of patients in China.
"We will showcase several globally pioneering, best-in-class innovative products and breakthrough therapies from our core fields at this year's CIIE. At the same time, we will also present our digital innovation product, myPKFiT 3.0, and remarkable digital health achievements from TakedaSpark-incubated companies, continuing the brilliance of CIIE," said Shan Guohong, Global Senior Vice President of Takeda Pharmaceutical Company Limited and President of Takeda China.
It is reported that, thanks to the "spillover effect" of the CIIE and the strong measures taken by the Chinese government to optimize the approval process and accelerate the approval of new drugs, more than 10 innovative drugs and breakthrough indications showcased at the CIIE have been approved for marketing in China since 2020. Seven innovative products have been included in the national medical insurance catalog, setting new records in terms of the speed and number of approvals for market entry in China.
After nearly three decades of development, Takeda has now ranked among the top ten multinational pharmaceutical companies in the Chinese market. In recent years, Takeda China has entered a new high-speed growth cycle, with a compound annual growth rate exceeding 30% from 2020 to 2022.